Samya Chakravorty

About

I am a molecular and human geneticist, and muscle biologist, with training in cardiac/skeletal muscle physiology and genetics of neuromuscular disorders. I am working on developing methods for translation of functional genomics and molecular assays to clinical care for faster, more precise diagnosis and precise, targeted therapies including neuromuscular disease as main focus along with childhood neuropathies, and more recently host genomics in pediatric COVID-19.

Employment

• Emory University Department of Pediatrics Atlanta GA US Associate Scientist
  2020 - Present
• Children's Healthcare of Atlanta
  2020 - Present
• Emory University Department of Pediatrics Senior Postdoctoral Fellow
  2019 - 2020
• Emory University Department of Human Genetics Senior Postdoctoral Fellow
  2016 - 2019
• Lee Kong Chian School of Medicine Teaching Faculty (Team-Based Learning Facilitator)
  2014 - 2016
• Lee Kong Chian School of Medicine Postdoctoral Fellow
  2013 - 2016
• University of Vermont Department of Biology Graduate Teaching Assistant
  2007 - 2013
• Neotia Institute of Technology Management and Science Department of Biotechnology Visiting Lecturer
  2006 - 2007
• University of Calcutta University College of Science Technology and Agriculture Research Associate
  2006 - 2007
• Indian Institute of Chemical Biology CSIR Research Associate
  2005 - 2006

Education

• University of Vermont Department of Biology Ph.D in Biology
  2007 - 2013
• West Bengal University of Technology BS (Engineering) in Biotechnology
  2002 - 2006

Projects & Funding

Projects & funding information is unavailable.

Publications (17)

• Utilization of Targeted RNA-Seq for the Resolution of Variant Pathogenicity and Enhancement of Diagnostic Yield in Dysferlinopathy
  Journal of Personalized Medicine 2023 DOI: 10.3390/jpm13030520
  +Save
• Expanding the genotype–phenotype correlation of childhood sensory polyneuropathy of genetic origin
  Scientific Reports 2020 DOI: 10.1038/s41598-020-73219-5
  +Save
• Reply: Autosomal dominant segregation of CAPN3 c.598_612del15 associated with a mild form of calpainopathy.
  Annals of clinical and translational neurology 2020 DOI: 10.1002/acn3.51192
  +Save
• Auto-antibodies against type I IFNs in patients with life-threatening COVID-19.
  Science (New York, N.Y.) 2020 DOI: 10.1126/science.abd4585
  +Save
• Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.
  Science (New York, N.Y.) 2020 DOI: 10.1126/science.abd4570
  +Save
• Clinical and Genomic Evaluation of 207 Genetic Myopathies in the Indian Subcontinent
  medRxiv 2020 DOI: 10.1101/2020.09.15.20193425
  +Save
• Clinical utility of RNA sequencing to resolve unusual GNE myopathy with a novel promoter deletion.
  Muscle & nerve 2019 DOI: 10.1002/mus.26486
  +Save
• Genetic landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients
  Annals of Clinical and Translational Neurology 2018 DOI: 10.1002/acn3.649
  +Save
• Why west? Comparisons of clinical, genetic and molecular features of infants with and without spasms
  PLoS ONE 2018 DOI: 10.1371/journal.pone.0193599
  +Save
• Inferring the effect of genomic variation in the new era of genomics
  Human Mutation 2018 DOI: 10.1002/humu.23427
  +Save